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In breast cancer there are many novel molecule-targeted
therapies in preclinical and clinical development. For the
majority, if not all, of these therapies there is no clear
biomarker profile in tumours to inform the inclusion or
exclusion of patients into phase II efficacy trials of these
drugs or combinations that include them. Some data suggest
that short-term, tissue-based pharmacodynamic trials in newly
diagnosed early-stage operable cancers provide information
that can be later used in patient selection. For example,
administration of anti-oestrogens for a period of 1 to 3 weeks
has been shown to induce a significant antiproliferative effect
in oestrogen receptor (ER)-positive breast cancers [1-3].
These studies have evaluated proliferation in the tumour by
measuring the percentage of cells that stain with an antibody
against the nuclear antigen Ki67 [4]. Interestingly, in all of
these trials there was no effect in the ER-negative cancers.
In other neoadjuvant trials, short-term end-points have corre-
lated with clinical outcome. For example, treatment-induced
tumour cell apoptosis, as measured by cleaved caspase-3
immunohistochemistry 1 week after administration of the anti-
human epidermal growth factor receptor (HER)-2 monoclonal
trastuzumab, correlates with clinical response of HER-2 over-
expressing breast cancers [5]. The neoadjuvant Immediate
Preoperative Anastrozole Tamoxifen or Combined with
Tamoxifen (IMPACT) trial compared anastrozole versus
tamoxifen versus the two drugs combined. Drug-induced
inhibition of tumour cell proliferation at 2 weeks, as measured
using Ki67, was better in patients treated with anastrozole
than in patients included in the other two arms [6]. This
finding parallels the results of the large Anastrozole,
Tamoxifen, Alone or in Combination (ATAC) adjuvant trial, in
which relapse-free survival was greater in patients treated
with adjuvant anastrozole than in those receiving tamoxifen or
the combination [7].
Recent pharmacodynamic studies of epidermal growth factor
receptor (EGFR) inhibitors have provided some clues that
might be of clinical use, as this approach can be potentially
applied to other novel compounds and/or combinations. Guix
and coworkers [8] administered erlotinib for 6 to 14 days to
women with operable untreated breast cancer in order to
identify a biomarker associated with evidence of drug-
mediated cellular activity in the surgical specimen. Erlotinib
inhibited cell proliferation (Ki67) and phosphorylated EGFR,
mitogen-activated protein kinase (MAPK), Akt and S6 only in
ER-positive tumours, and not in HER-2-positive or triple
negative tumours. These data are consistent with at least
three reports showing that clinical activity of gefitinib appears
to be limited to ER-positive breast cancers [9-11].
Interestingly, erlotinib inhibited phosphorylation of ER-α in
Ser118. Similar results were reported by Polychronis and
coworkers [11] in ER-positive/EGFR-positive newly diag-
nosed breast cancers treated for 6 weeks with neoadjuvant
gefitinib. Because phosphorylation of this site is regulated
mainly by MAPK [12], these findings provide evidence of
operative crosstalk between ER and ErbB receptor signalling
early in the natural history of hormone-dependent breast
cancer. In addition, they imply that the use of EGFR
antagonists in combination with anti-oestrogens should be
explored in further clinical trials.
Indeed, preliminary communication of results from clinical
trials already suggests this strategy to be effective. Cristo-
fanilli and coworkers [13] recently reported the results of a
randomized phase II study of anastrozole plus gefitinib versus
anastrozole plus placebo in postmenopausal women with
hormone receptor positive metastatic breast cancer. Fifty
patients received anastrozole plus placebo and 43 the
aromatase and EGFR inhibitors combined. Patients treated
with this combination exhibited a median progression-free
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survival (PFS) of 14.5 months, as compared with 8.1 months
in the anastrozole plus placebo control arm of the trial.
Follow-up was too short to estimate overall survival. A similar
randomized phase II trial was reported by Osborne and
coworkers [14]. Patients with new ER-positive metastatic
disease or who had recurred after adjuvant tamoxifen or had
recurred during or after adjuvant therapy with an aromatase
inhibitor were randomly assigned to tamoxifen with/without
gefitinib. The PFS was 10.9 months versus 8.8 months in the
combination versus the tamoxifen arm, with a PFS hazard
ratio of 0.84 [14].
The results of these two studies in patients with ER-positive
metastatic disease should be contrasted with those of a
16-week neoadjuvant trial of anastrozole with/without gefitinib
in patients with stage I to IIIB ER-positive breast cancer [15].
In this study, objective response exhibited a nonsignificant
trend against the combination versus the anastrozole arm
(48% versus 61%). This difference was statistically signifi-
cant in the progesterone receptor positive group. Lack of
patient selection, prior adjuvant therapy, different stage of
disease (localized versus metastatic) and study end-points
(response versus PFS) may potentially account for the
discrepancy in results.
The presurgical studies discussed above support the feasibility
of testing novel therapies during the pre-approval process to
investigate a tumour profile of potential use in subsequent
clinical studies that address drug efficacy. This approach
requires additional examples and experience. We speculate,
though, that this trial design may expedite the drug development
process by potentially informing the exclusion of nonresponsive
patients who will dilute the net signal of clinical activity of a drug
or a combination. In the case of erlotinib, these patients would
be those with HER-2-positive and triple-negative, basal-like
cancers. Interestingly, because of its relative over-expression in
breast cancers with a basal-like gene expression signature [16],
the EGFR has been proposed as a therapeutic target in
tumours that lack ER and HER-2. However, in two recent trials
in patients with triple-negative, basal-type metastatic breast
cancer, the addition of the EGFR antibody cetuximab did not
add to the effect of chemotherapy [17,18].
In summary, we believe that the evaluation of biological agents
in early-stage breast cancer, where tumour tissue is available,
provides outstanding opportunities for accelerated drug
development, biomarker discovery and, eventually, patient
selection. It can potentially validate inhibition of the molecular
target of the drug; identify subgroups of patients who may not
be candidates for the drug in question (triple negative tumours
for EGFR inhibitors, to follow the example above); and provide
knowledge to assist in a ‘go versus no-go’ decision regarding
progression to phase II or III drug development.
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